Grifols, S.A. American Depositary Receipt (GRFS)
Grifols: Better Plasma Economics Can Unlock A Discounted Equity
Grifols is shifting to regional plasma sourcing, aiming for durable cash generation over headline catalysts like a U.S. listing or refinancing. I see improved cash flow as contingent on better sourcing economics, higher network productivity, and incremental plasma protein revenues, not just revenue growth. Despite a 30%+ EV/EBITDA discount to peers, GRFS's value hinges on operational improvements and cash conversion, not simply low multiples.
GRFS or SDZNY: Which Is the Better Value Stock Right Now?
Investors interested in Medical - Drugs stocks are likely familiar with Grifols (GRFS) and Sandoz Group AG Sponsored ADR (SDZNY). But which of these two companies is the best option for those looking for undervalued stocks?
Grifols Q2 Earnings Call Highlights
Grifols NASDAQ: GRFS said its second-quarter and first-half results kept the plasma-derived medicines company on track to meet its 2026 objectives, supported by continued growth in immunoglobulins, improving free cash flow and progress in its plasma-sourcing strategy.
Grifols: Operational Recovery And Balance Sheet Improvement Support A Return To Buy (Rating Upgrade)
First-quarter results were broadly in line with expectations, supported by strong growth in the Biopharma division, particularly immunoglobulins, where products such as Gamunex and Yimmugo continue to outperform. Grifols successfully refinanced all 2027 debt maturities ahead of schedule, extending maturities, lowering funding costs, and reducing refinancing risk. Lower plasma collection costs (with the Egyptian plasma platform), optimization of the U.S. collection network, and continued Biotest integration are expected to support sustainable margin expansion.
Grifols: Plasma Self-Sufficiency Is The Mispriced Catalyst
Grifols is transitioning from a leveraged recovery story to a strategic plasma infrastructure leader with global scale and supply security advantages. GRFS trades at a significant valuation discount—forward P/E of 8.42x and price/cash flow of 4.76x—despite robust EBITDA, margin expansion, and improving free cash flow. Recent refinancing pushes major debt maturities to 2028; management guides for 2026 EBITDA margins of at least 25% and €500–€575 million free cash flow pre-dividends.
Grifols, S.A. (GIKLY) Q1 2026 Earnings Call Transcript
Grifols, S.A. (GIKLY) Q1 2026 Earnings Call Transcript
Grifols: I'm Very Happy To Add In 2026
Grifols is a global leader in blood plasma, now rated 'BUY' with a €20/share PT and $23/share ADR target. GRFS has delivered €450M in cost savings, 150%+ net profit growth, and FCF exceeding guidance, with leverage down to 4.2x. Despite a BB- rating, improved fundamentals, dividend reinstatement, and forecasted 20–25% annual growth support a strong risk/reward profile.
Grifols, S.A. (GIKLY) Q4 2025 Earnings Call Transcript
Grifols, S.A. (GIKLY) Q4 2025 Earnings Call Transcript
Grifols: Positive/Neutral Scenario Posits An Upside
Grifols, S.A. has executed a turnaround, with Q3 '25 results confirming improved fundamentals, reduced leverage, and restored dividend, supporting a renewed 'Buy' rating. GRFS now trades at a normalized P/E of 14-15x, but forward multiples drop below 9x, offering significant upside if growth forecasts materialize. Operational improvements include 7%+ revenue growth, double-digit EBITDA gains, positive FCF, and leverage below 4.3x, with further refinancing underway.
Grifols, S.A. (GIKLY) Q3 2025 Earnings Call Transcript
Grifols, S.A. (OTCPK:GIKLY) Q3 2025 Earnings Call November 4, 2025 12:30 PM EST Company Participants Daniel Segarra - Head of Investor Relations & Sustainability and Vice President Jose Ignacio Abia Buenache - CEO & Director Roland Wandeler - President of Biopharma Business Unit Rahul Srinivasan - Chief Financial Officer Conference Call Participants Charles Pitman - Barclays Bank PLC, Research Division Jaime Escribano - Banco Santander, S.A.
Is Grifols (GRFS) Stock Outpacing Its Medical Peers This Year?
Here is how Grifols (GRFS) and Arcutis Biotherapeutics, Inc. (ARQT) have performed compared to their sector so far this year.
GRFS vs. ZTS: Which Stock Is the Better Value Option?
Investors looking for stocks in the Medical - Drugs sector might want to consider either Grifols (GRFS) or Zoetis (ZTS). But which of these two stocks offers value investors a better bang for their buck right now?
